Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer

Oncogene

Volumn 33, Issue 33, 2014, Pages 4213-4225

  Dey, P ^a   Strom A ^a   Gustafsson, J A ^a,b  

^a University of Houston   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

apoptosis; ER ; FOXO3a; p53; PUMA

Indexed keywords

CASPASE 9; CYTOCHROME C; ESTROGEN RECEPTOR BETA; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; PUMA PROTEIN; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIUM BASAL CELL; ESTROGEN RESPONSIVE ELEMENT; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE VENTRAL LOBE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; UPREGULATION;

MUS;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; ESTROGEN RECEPTOR BETA; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, NUDE; NEOPLASM GRADING; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84906283646     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.384     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012CA Cancer J Clin 2012; 62: 10-29.
2. Cornforth AN, Davis JS, Khanifar E, Nastiuk KL, Krolewski JJ. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene 2008; 27: 4422-4433.
3. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-682. (Pubitemid 32706358)
4. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exper Med 2006; 203: 1657-1663. (Pubitemid 44036270)
5. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868. (Pubitemid 29165088)
6. Tran H, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002; 296: 530-534. (Pubitemid 34408672)
7. Yamamoto M, Kondo E, Takeuchi M, Harashima A, Otani T, Tsuji-Takayama K et al. miR-155, a modulator of FOXO3a protein expression, is underexpressed and cannot be upregulated by stimulation of HOZOT, a line of multifunctional Treg. PLoS One 2011; 6: e16841.
8. Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC et al. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res 2008; 10: R21.
9. Giroux V, Bernatchez G, Carrier JC. Chemopreventive effect of ERbeta-Selective agonist on intestinal tumorigenesis in Apc(Min/+) mice. Mol Carcinogen 2011; 50: 359-369.
10. Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC. Estrogen receptor beta deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. International journal of cancer. J Int Cancer 2008; 123: 303-311. (Pubitemid 351842014)
11. Saleiro D, Murillo G, Lubahn DB, Kopelovich L, Korach KS, Mehta RG et al. Enhanced induction of mucin-depleted foci in estrogen receptor {beta} knockout mice. Cancer Prev Res (Phila) 2010; 3: 1198-1204.
12. Slusarz A, Jackson GA, Day JK, Shenouda NS, Bogener JL, Browning JD et al. Aggressive prostate cancer is prevented in ERalphaKO mice and stimulated in ERbetaKO TRAMP mice. Endocrinology 2012; 153: 4160-4170.
13. Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M et al. Potential role of estrogen receptor Beta as a tumor suppressor of epithelial ovarian cancer. PLoS One 2012; 7: e44787.
14. Dey P, Jonsson P, Hartman J, Williams C, Ström A, Gustafsson JÅ et al. Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 2012; 26: 1991-2003.
15. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64: 423-428. (Pubitemid 38114127)
16. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA et al. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004; 101: 1566-1571. (Pubitemid 38236167)
17. McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 2010; 107: 3123-3128.
18. Hussain S, Lawrence MG, Taylor RA, Lo CY, Frydenberg M, Risbridger GP et al. Estrogen receptor beta activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations. PLoS One 2012; 7: e40732.
19. Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 2008; 109: 241-250. (Pubitemid 351644839)
20. Ji Q, Liu PI, Elshimali Y, Stolz A. Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol Cell Endocrinol 2005; 229: 103-110. (Pubitemid 40018088)
21. Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L et al. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocrine Relat Cancer 2010; 17: 675-689.
22. Oliveira AG, Coelho PH, Guedes FD, Mahecha GA, Hess RA, Oliveira CA et al. 5alpha-Androstane-3beta,17beta-diol (3beta-diol), an estrogenic metabolite of 5alpha-dihydrotestosterone, is a potent modulator of estrogen receptor ERbeta expression in the ventral prostrate of adult rats. Steroids 2007; 72: 914-922. (Pubitemid 47600274)
23. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002; 99: 13589-13594. (Pubitemid 35221316)
24. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/ threonine kinase Akt/PKB. Exp Cell Res 1999; 253: 210-229.
25. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-7425. (Pubitemid 41637981)
26. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-5930. (Pubitemid 26190778)
27. Cvoro A, Paruthiyil S, Jones JO, Tzagarakis-Foster C, Clegg NJ, Tatomer D et al. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology 2007; 148: 538-547. (Pubitemid 46150775)
28. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC et al. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 2006; 21: 555-564. (Pubitemid 43228010)
29. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann NY Acad Sci 2009; 1155: 174-186.
30. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010; 17: 319-332.
31. Dondi D, Piccolella M, Biserni A, Della Torre S, Ramachandran B, Locatelli A et al. Estrogen receptor beta and the progression of prostate cancer: role of 5alphaandrostane- 3beta,17beta-diol. Endocrine Relat Cancer 2010; 17: 731-742.
32. Saijo K, Collier JG, Li AC, Katzenellenbogen JA, Glass CK. An ADIOL-ERbeta-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell 2011; 145: 584-595.
33. Muthusamy S, Andersson S, Kim HJ, Butler R, Waage L, Gustafsson JÅ et al. Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci USA 2011; 108: 20090-20094.
34. Olsson M, Gustafsson O, Skogastierna C, Tolf A, Rietz BD, Morfin R et al. Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma. Prostate 2007; 67: 1439-1446. (Pubitemid 47435790)
35. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694. (Pubitemid 32706359)
36. Roberts CG, Millar EK, O'Toole SA, McNeil CM, Lehrbach GM, Pinese M et al. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene 2011; 30: 3186-3197.
37. Hartman J, Lindberg K, Morani A, Inzunza J, Ström A, Gustafsson JA et al. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006; 66: 11207-11213. (Pubitemid 46009948)
38. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009; 69: 6100-6106.
39. Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V et al. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J Mol Endocrinol 2004; 32: 777-791. (Pubitemid 38885645)
40. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S et al. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 2009; 119: 1093-1108.
41. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-1489.
42. Hartman J, Müller P, Foster JS, Wimalasena J, Gustafsson JA, Ström A et al. HES-1 inhibits 17beta-estradiol and heregulin-beta1-mediated upregulation of E2F-1. Oncogene 2004; 23: 8826-8833. (Pubitemid 39610444)
43. Helguero LA, Hedengran Faulds M, Forster C, Gustafsson JA, Haldosen LA. DAX-1 expression is regulated during mammary epithelial cell differentiation. Endocrinology 2006; 147: 3249-3259. (Pubitemid 43904302)